February 2026

Cure SMA Awards $75,000 Grant to Jiangbing Zhou, PhD, at Yale University

Leave a Comment / Front Page News, Our Impact, Research /

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to […]

Cure SMA Awards $75,000 Grant to Jiangbing Zhou, PhD, at Yale University Read More »

Cure SMA Awards $150,000 Grant to Emma Sutton, PhD, at Ottawa Hospital Research Institute in Canada

Leave a Comment / Front Page News, Our Impact, Research, Uncategorized /

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to

Cure SMA Awards $150,000 Grant to Emma Sutton, PhD, at Ottawa Hospital Research Institute in Canada Read More »

Cure SMA Awards $150,000 Grant to Anton Blatnik, PhD, at Case Western Reserve University

Leave a Comment / Front Page News, Latest News, Our Impact, Research /

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to

Cure SMA Awards $150,000 Grant to Anton Blatnik, PhD, at Case Western Reserve University Read More »

Biogen Announces Results from the Phase 2/3 DEVOTE Study

Leave a Comment / Front Page News, Industry Updates, Latest News, Research /

Today, Biogen announced the publication of results from the pivotal Phase 2/3 DEVOTE study in Nature Medicine, highlighting the potential benefits of a high-dose regimen of nusinersen for people living with spinal muscular atrophy (SMA). The study evaluated a higher loading and maintenance dose regimen of nusinersen and demonstrated improvements across key areas, including motor

Biogen Announces Results from the Phase 2/3 DEVOTE Study Read More »

SMA Community Research and Legislative Priorities Finalized in New Federal Law

Leave a Comment / About SMA, Advocacy, Front Page News, Latest News /

On February 3rd, Congress approved and the President signed into law key research and legislative priorities that Cure SMA and individuals with spinal muscular atrophy (SMA) and their families have been advocating for over the past year. The Consolidated Appropriations Act of 2026 includes the following provisions that will benefit children and adults with SMA

SMA Community Research and Legislative Priorities Finalized in New Federal Law Read More »

Scroll to Top